<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01059266</url>
  </required_header>
  <id_info>
    <org_study_id>P/0035</org_study_id>
    <nct_id>NCT01059266</nct_id>
  </id_info>
  <brief_title>PURETHAL Grasses Rush Study</brief_title>
  <official_title>A Prospective, Randomized, Open, Multi-centre Study to Assess Safety of PURETHAL Grasses Given With a Rush Induction Schedule to Patients With Allergic Rhinoconjunctivitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HAL Allergy</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>HAL Allergy</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study investigates the safety of two up-dosing regimen. The safety of PURETHAL Grasses&#xD;
      will be evaluated in a rush regimen (maximum dose reached in 3 injections during 2 weeks)&#xD;
      compared to the conventional regimen (maximum dose reached in 6 injections during 5 weeks).&#xD;
&#xD;
      The primary parameter will be the proportion of patients who experience systemic reactions &gt;&#xD;
      grade I within 24 hours after injection or who need more than 2 additional injections during&#xD;
      the up-dosing phase until the maintenance dose has been reached.&#xD;
&#xD;
      It is expected that up-dosing PURETHAL Grasses according to the rush regimen is as safe as&#xD;
      using the conventional regimen.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>systemic reactions &gt; grade I or large local reactions related to injection</measure>
    <time_frame>24 hrs after injection</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>specific serum IgE and IgG concentrations</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Allergic Rhinitis</condition>
  <condition>Allergic Rhinoconjunctivitis</condition>
  <arm_group>
    <arm_group_label>conventional regimen of PURETHAL Grasses</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Initial treatment:&#xD;
6 incremental weekly subcutaneous doses of 0.05, 0.1, 0.2, 0.3, 0.4 and 0.5 ml (week 1, 2, 3, 4, 5, 6).&#xD;
Maintenance treatment:&#xD;
0.5 ml in intervals according to registered scheme (week 8, 10, 12, 16).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>rush regimen of PURETHAL Grasses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Initial treatment:&#xD;
3 incremental weekly subcutaneous doses of 0.1, 0.3, and 0.5 ml (week 1, 2, 3)&#xD;
Maintenance treatment:&#xD;
3 monthly doses of 0.5 ml (week 7, 11, 15).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PURETHAL Grasses, 20.000 AUM/ml</intervention_name>
    <description>subcutaneous injections of increasing doses according to the described regimen</description>
    <arm_group_label>conventional regimen of PURETHAL Grasses</arm_group_label>
    <arm_group_label>rush regimen of PURETHAL Grasses</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Patients with rhinitis or rhinoconjunctivitis, with or without mild asthma (FEV1 &gt;&#xD;
             70%) for at least 2 years related to grass pollen, eligible for SCIT.&#xD;
&#xD;
          -  Confirmation of IgE-mediated allergy by means of:&#xD;
&#xD;
               -  Positive SPT to grass pollen (mean wheal diameter ≥ 3 mm and negative control&#xD;
                  truly negative (no reaction), or&#xD;
&#xD;
               -  Specific serum IgE-test (ssIgE &gt;0.7 U/ml) for grass pollen, or&#xD;
&#xD;
               -  Positive provocation test for grass pollen.&#xD;
&#xD;
          -  Age ≥ 18 years.&#xD;
&#xD;
          -  Patients have given a written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Chronic asthma or emphysema, particularly with a FEV1 ≤ 70% of predicted value.&#xD;
&#xD;
          -  Serious immuno-pathological diseases or malignancies (including auto-immune diseases,&#xD;
             tuberculosis, HIV).&#xD;
&#xD;
          -  Active inflammation/infection of the target organs (nose, eyes, lungs).&#xD;
&#xD;
          -  Severe atopic dermatitis in need for systemic immunosuppressive medication.&#xD;
&#xD;
          -  Symptomatic coronary heart diseases (e.g heart failure, recent myocardial infarction,&#xD;
             unstable angina, serious arrhythmias) or severe (even under treatment) arterial&#xD;
             hypertension.&#xD;
&#xD;
          -  Severe kidney disease.&#xD;
&#xD;
          -  Diseases with a contra-indication for the use of adrenaline.&#xD;
&#xD;
          -  Treatment with systemic or local beta-blockers or immunosuppressive drugs.&#xD;
&#xD;
          -  History of life threatening anaphylactic events, including anaphylactic food allergy,&#xD;
             insect venom anaphylaxis, exercise or drug induced anaphylaxis.&#xD;
&#xD;
          -  Any specific immunotherapy (including sublingual) during the study period or during&#xD;
             the previous 3 years for a period longer than three months.&#xD;
&#xD;
          -  Participation in a clinical study with a new investigational drug within the last&#xD;
             three months.&#xD;
&#xD;
          -  Pregnancy, lactation or inadequate contraceptive measures (adequate measures: oral&#xD;
             contraceptives, IUD, condom use if used together with a spermicide and having no&#xD;
             sexual relationship with a man).&#xD;
&#xD;
          -  Alcohol or drug abuse.&#xD;
&#xD;
          -  Lack of co-operation or severe psychological disorders.&#xD;
&#xD;
          -  Completed or ongoing long-term treatment with tranquilizer or psycho active drugs.&#xD;
&#xD;
          -  Low compliance or inability to understand instructions/study documents.&#xD;
&#xD;
          -  Completed or ongoing treatment with anti-IgE-antibody.&#xD;
&#xD;
          -  Patients being in relationship or dependence with the sponsor or investigator.&#xD;
&#xD;
          -  Allergy to any of the excipients.&#xD;
&#xD;
          -  Severe illness or any other condition, which makes the patient, in the opinion of the&#xD;
             investigator, unsuitable for the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Oliver Pfaar, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Zentrum für Rhinologie &amp; Allergologie, An den Quellen 10, D - 65183 Wiesbaden</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitätsklinikum Bonn Klinik u. Poliklinik f. Dermatologie</name>
      <address>
        <city>Bonn</city>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Practice Blum</name>
      <address>
        <city>Dortmund</city>
        <zip>44263</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uni-Klinikum Carl Gustav Carus Klinik und Poliklinik für HNO</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Practice Thieme</name>
      <address>
        <city>Duisburg</city>
        <zip>47051</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medaimun GmbH</name>
      <address>
        <city>Frankfurt</city>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Practice Wrede</name>
      <address>
        <city>Herford</city>
        <zip>32052</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. med. Jörg Michael Nebel</name>
      <address>
        <city>Koblenz</city>
        <zip>56072</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Practice Scholz</name>
      <address>
        <city>Mahlow</city>
        <zip>15831</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Kamillus Krankenhaus Abt. Lungen- und Bronchialheilkunde und Allergologie</name>
      <address>
        <city>Mönchengladbach</city>
        <zip>41069</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Practice Termeer</name>
      <address>
        <city>Stuttgart</city>
        <zip>70499</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zentrum für Rhinologie &amp; Allergologie</name>
      <address>
        <city>Wiesbaden</city>
        <zip>D - 65183</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <study_first_submitted>January 28, 2010</study_first_submitted>
  <study_first_submitted_qc>January 28, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 29, 2010</study_first_posted>
  <last_update_submitted>February 9, 2012</last_update_submitted>
  <last_update_submitted_qc>February 9, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 10, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>immunotherapy</keyword>
  <keyword>grass pollen</keyword>
  <keyword>seasonal allergy</keyword>
  <keyword>dose tolerability</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
    <mesh_term>Conjunctivitis, Allergic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

